We are very proud to contribute with our expertise in phenotypic and functional profiling of cardiac muscle disorders as a partner of another European consortium of excellence.
“IMPACT, Cardiogenomics meets Artificial Intelligence: a step forward in arrhythmogenic cardiomyopathy (ACM) diagnosis and treatment” aims at establishing a genotype/cardiac phenotype relationship by combining large-scale data from genomics, proteomics and instrumental analysis, obtained from patients, with data from structural and functional analyses of in vitro (3D microtissue) and in vivo (murine) models.
The consortium is composed of 7 partners from Academia, Hospitals, Biotechs and Pharma.